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Preparation and in vitro and in vivo evaluation of vinpocetine (VIN) elementary osmotic pump (EOP) formulations were
investigated. A method for the preparation of VIN elementary osmotic pump tablet was obtained by adding organic acid
additives to increase VIN solubility. VIN was used as the active pharmaceutical ingredient, lactose and mannitol as osmotic agent.
Citric acid was used as increasing API solubility and without resulting in the API degradation. It is found that the VIN release
rate was increasing with the citric acid amount at a constant range. Cellulose acetate 398-3 was employed as semipermeable
membrane containing polyethylene glycol 6000 and diethyl-o-phthalate as pore-forming agent and plasticizer for controlling
membrane permeability. In addition, a clear diﬀerence between the pharmacokinetic patterns of VIN immediate release and
VIN elementary osmotic pump formulations was revealed. The area under the plasma concentration-time curve after oral
administration of elementary osmotic pump formulations was equivalent to VIN immediate release formulation. Furthermore,
signiﬁcant diﬀerences found for mean residence time, elimination half-life, and elimination rate constant values corroborated
prolonged release of VIN from elementary osmotic pump formulations. These results suggest that the VIN osmotic pump
controlled release tablets have marked controlled release characters and the VIN osmotic pump controlled release tablets and
the normal tablets were bioequivalent.
1.Introduction
Vinpocetine (VIN) is a vasoactive vinca alkaloid and a
synthetic derivative of apovincamine which has been used
in clinical practice in Europe for 30 years for the treat-
ment of disorders arising from cerebrovascular and cerebral
degenerative diseases [1, 2]. VIN is thought to increase
the cerebral blood ﬂow in the ischemic areas of patients
with cerebrovascular disease, decrease platelet aggregability
in patients with transient ischemic attack or stroke, increase
red blood cell deformability in stroke patients, and have
neuroprotective abilities and a protective eﬀect against brain
ischemia [3, 4].
VIN is mainly used as immediate oral dosage forms
containing 5mg of the active ingredient, with a daily dosage
regimen that can vary between 5mg × 3/day to 20mg
× 3/day [5]. Conventional preparation will lead to large
ﬂuctuation in drug plasma concentration and side eﬀect on
human body. Constant plasma level can oﬀer a therapeutic
advantage for many drugs in terms of both eﬃcacy and
tolerance of the treatment [6]. Once-daily controlled release
preparation is often desirable.
Research about sustained-release formulations of VIN
had been reported. Ribeiro et al. [7, 8] reported that Vin-
cyclodextrin-tartaric acid multicomponent complexation
was prepared and an optimal formulation was then designed
by the combination of these complexes into HPMC-based
hydrophilic tablet dosage forms. Results supported the use
of HPMC matrices to provide a useful tool in retarding the
release of VIN and that dissolution characteristics of the
drug may be modulated by multicomponent complexation
in above delivery systems. Nie et al. [9] had successfully
prepared HPMC sustained-release matrix tablets containing
citric acid. Cao et al. [10] reported the push-pull osmotic2 Advances in Pharmacological Sciences
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Scheme 1: The chemical structure of VIN.
pump tablet preparation of VIN and in vivo/in vitro
evaluation.
The osmotic pump tablet that holds a prominent place
among controlled release systems has many advantages,
such as reducing the risk of adverse reactions, improving
complianceofpatients,andexhibitingcomparableinvitro/in
vivo drug release.
The ﬁrst osmotic pump for delivery of active ingredients
was invented by Rose and Nelson in the 1950s [11]. The
ﬁrstcommercialosmoticdevicewasintroducedbyTheeuwes
known as elementary osmotic pump (EOP) in the 1970s
[12]. The EOP was a core tablet coated by semipermeable
membrane with a micro-oriﬁce drilled on the surface. The
EOP was simpler than push-pull osmotic pump reported by
Cao et al.[10] in preparation and could deliver water-soluble
drugs at an approximately constant rate up to 12h. However,
V I Ni sap o o r l yw a t e r - s o l u b l eb a s et y p ed r u g( Scheme 1).
S o ,i ti sc r i t i c a lt oi m p r o v ed r u gs o l u b i l i t i e s .I tw a sr e p o r t e d
that a method for the preparation of water-soluble drug was
obtained by adding acid additives to increase dissolution and
improve the release proﬁle [13, 14]. In the present paper,
preparationwithcitricacidincoretabletsandinvitro/invivo
evaluation were investigated.
2.MaterialsandMethods
Materials. VIN (Changchun Pharmaceutical Co., Ltd.,
China) was API. Citric acid (Beijing Fengli Jingqiu Ltd.,
China) was used as increasing dissolution. Lactose (Beijing
Fengli Jingqiu Ltd., China) and mannitol (Beijing Fengli
Jingqiu Ltd., China) were used as osmotic agent. PVP K30
(Beijing Fengli Jingqiu Ltd., China), HPMC K4M (Beijing
Fengli Jingqiu Ltd., China), and Magnesium Steric (Beijing
Fengli Jingqiu Ltd., China) were used as binder, retarder,
and lubricate, respectively. Cellulose acetate 398-3 (Estman
Co., Ltd., USA) was employed as semipermeable membrane
containing polyethylene glycol 6000 (PEG-6000, Beijing
FengliJingqiuLtd.,China)asplasticizer,Diethyl-o-phthalate
(Beijing Jingqiu Ltd., China) as pores-forming agent, and
acetone (Beijing Chemical Agent Ltd., China) as solvent for
controlling membrane permeability. Other chemicals used
were of analytical grade.
Preparation of Core Tablets. VIN powder was mixed with
lactose, mannitol, HPMC K4M, and PVP K30 manually
using 70% ethanol solution as binder, and then the mixture
was passed through an 850 ± 29µm sieve to generate
granules and dried at 45◦C for 4h. Then the above-
mentioned mixture was sifted by a 1375-µms i e v e .T h e
resultant granules were compressed into core tablet using
the PXD single-punch tableting machine (Beijing Hangtian
Changfeng Pharmaceutical Device Co., Ltd., China). The
weight of each core tablet was maintained within the
range of (180 ± 5%)mg. The hardness of the core tablets
was kept within (60∼120) N (Hardness tester, Shanghai
Huanghai Drug Inspection Instrument Co., Ltd., China).
The relative humidity of surrounding environment should
be kept below 50%.
CoatingandDrying. CAin95%acetone(%,w/v)containing
plasticizer (PEG-6000) and diethyl-o-phthalate was used as
coating solution. The coating was carried out in a pan coater
(BY300·fa, Jiangsu Taizhou Drug Development Instrument
Co., Ltd., China). The temperature of coating pan was
30∼40◦C; pan-rotating rate was 20rpm. The coated tablets
were dried to remove the residual solvent acetone and water
at 40◦C for 24h, and laser machines (Jiangsu Meilin Co.,
Ltd., China) drilled an oriﬁce on the membrane surface.
UV Analysis of VIN. The detection wavelength was 268nm.
Linear correlation was obtained between peak area versus
concentration of VIN in the range of 2.118∼31.77µg/mL.
Each measurement represented the average of three repli-
cates. The regression equation was found to be A =
0.0317C +0 .0046, r = 1.000, where A is the peak area and
C is the concentration of VIN in 2.118∼31.77µg/mL.
In Vitro Release Test. In vitro drug release test was conducted
in a dissolution apparatus (D-800LS, Precise Apparatus of
Tianjin University Co., Ltd, China) using the Basket method
according to Ch.P (Chinese Pharmacopoeia edition 2005).
The temperature of the release medium was maintained
at 37 ± 0.5◦C and the rotation speed of the basket was
adjusted to 100rpm. Samples of 10mL were withdrawn
at 2.0, 4.0, 6.0, 8.0, 12.0, 14.0, and 24.0h and replaced
10.0mL fresh release media to each vessel. The solution
was immediately ﬁltered through a 0.45µm membrane ﬁlter,
suitably diluted and determined at 268nm using the Cintra
10e spectrophotometer. All experiments were performed in
triplicate.
In Vivo Studies Pharmacokinetic Studies in Dogs. Regarding
all animal studies, the research adhered to the “Principles
of Laboratory Animal Care”. For pharmacokinetic studies,
a group of three male beagle dogs was used and the
formulations were administered in a crossover fashion. The
VIN formulations were administered to fasted dogs and
immediately followed by an oral gavage of 50mL water. As
a control, an immediate-release tablet formulation (Zhejiang
Tailison Pharmaceutical Co. Ltd.) was administered.
After dosing, dogs were returned to metabolism cages
equippedwithautomatedwatersupplies.Theywerefedtheir
normal diet 8h after dosing on the day of the study. The dogs
remained in the metabolism cages until all of the tablets had
been recovered. Whole blood samples (2.0mL) were takenAdvances in Pharmacological Sciences 3
Table 1: Composition for core tablets with various molar ratios of vinpocetine and citric acid (unit:mg).
Vin:citricacid 1:0 1:1/3 1:2/3 1:1 1:4/3 1:6/3 1:7/3
Vinpocetine 15.0 15.0 15.0 15.0 15.0 15.0 15.0
Citric acid 0 2.74 5.48 8.22 10.96 16.44 19.2
Lactose 70.17 69.25 68.34 67.43 66.51 64.69 63.77
Mannitol 140.33 138.5 136.68 134.85 133.02 129.37 127.53
HPMCK4M 7.5 7.5 7.5 7.5 7.5 7.5 7.5
PVPK29–32 15.0 15.0 15.0 15.0 15.0 15.0 15.0
M.S. 2.0 2.0 2.0 2.0 2.0 2.0 2.0
Table 2: Cumulative dissolution of core tablets and release of coating tablets in 0.5% SDS and water.
Molarratiosofvinandcitricacid 1:0 1:1/3 1:2/3 1:1 1:4/3 1:6/3 1:7/3
Cumulative dissolution % 4.23 11.96 14.55 30.60 55.56 66.42 91.02
Cumulative release % 19.76 30.13 51.50 54.35 71.57 84.76 92.41
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Figure 1: Inﬂuence of molar ratio of citric acid and vinpocetine on
drug dissolution proﬁle (core tablets in water dissolution media);
VIN: vinpocetine; CA: citric acid.
from the jugular vein of each dog using 5-mL disposable
syringesbeforedosingandat0.5,1,1.5,2,3,4,6,8,10,14,24,
30, 36, and 48h after dosing for immediate release tablets/at
1, 2, 3, 4, 6, 8, 10, 14, 24, 30, 36, 48, and 60h after dosing
for controlled release tablets. The samples were immediately
transferred to heparinized (sodium heparin) Vacutainersk.
Sampleswerespunina5◦Ccentrifugeat3000rpmfor5min.
The plasma samples were poured into 2-mL plastic tubes.
Samples were frozen and stored in a freezer until they were
analyzedforVIN,usuallywithinaperiodof1month.HPLC-
MS-MS (Aglient 1200HPLC + Agilent 6410 Triple Quad
LC/MS (ESI)) method was to be adopted to analyse in vivo
samples.
The plasma-concentration-versus-time proﬁles were
analyzed using standard pharmacokinetic analysis tech-
niques. Peak plasma concentrations (Cmax) were determined
by inspection of the data. The ﬁrst occurrence of Cmax was
Table 3: Coating formulations.
Components Quantity
CA 398-3 4.5g
PEG-6000 1.35g
Acetone∗ 95.0mL
Diethyl-o-phthalate 1.0mL
Water∗ 5.0mL
Total 100.0mL
∗Major part of the acetone had been removed during coating. And the
residual solvent acetone and water at 40◦C for 24h could be removed after
coating.
deﬁned as the Tmax. Areas under the plasma-concentration-
time curves (AUC) were calculated by the linear trapezoidal
method using 3P97 Professional (Chinese pharmacologi-
calassociation software). Pharmacokinetic parameters were
dose-normalizedforeaseofcomparisonwiththeimmediate-
release control. Relative bioavailability (RBA) was deﬁned as
the dose-corrected AUC0−∞ of the osmotic pump controlled
release formulation divided by the dose-corrected AUC0−∞
of the immediate-release tablet.
3. Results and Discussion
3.1. Inﬂuence of Citric Acid on Drug Release Proﬁle. In
order to study the inﬂuence of citric acid amount on drug
dissolution,coretabletswithvariousmolarratiosofVINand
citric acid formulations in Table 1 were prepared and were
investigated. Dissolution proﬁle in water. Figure 1 showed
that the VIN dissolution was increasing as the citric acid
amount increased, which was in accordance with the report
[9]. When the molar ratio of VIN and citric acid was 1:7/3,
the cumulative dissolution was above 90%. It could be
concludedthattheratio(1:7/3)shouldbemuchmoresuited
for the solubilization of VIN.
Then, tablets with various ratios of VIN and citric acid
formulations were prepared coated with the same coating
formulation (Table 3) to study the inﬂuence of citric acid4 Advances in Pharmacological Sciences
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Figure 2: Formulation with diﬀerent molar ratio citric acid
and vinpocetine dissolution proﬁle (core tablets in 0.1N HCL
dissolution media); VIN: vinpocetine; CA: citric acid.
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Figure 3: Formulation with diﬀerent molar ratio citric acid
and vinpocetine dissolution proﬁle (core tablets in 0.5% SDS
dissolution media); VIN: vinpocetine; CA: citric acid.
amount on drug release in two diﬀerent release media (0.1N
HCL, 0.5% SDS solution). The VIN could be dissolved in
those two release media (see Figures 2 and 3)i no r d e r
to investigate the function of citric acid. And another aim
was to study whether H+ existing in release media could
be penetrating through the semipenetrating membrane to
inﬂuence the drug release, whose result should become a
basis for selecting optimal release media.
Figures 4 and 5 showed that the amount of citric acid
had a marked inﬂuence on VIN release. The tablet release
rate and cumulative release at 12h increased as the amount
of citric acid increased. Citric acid played a critical role in
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Figure 4: Inﬂuence of molar ratio of citric acid and vinpocetine
on drug release proﬁle (coating tablets in 0.1N HCL); VIN:
vinpocetine; CA: citric acid.
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Figure 5: Inﬂuence of molar ratio of citric acid and vinpocetine on
drugreleaseproﬁle(coatingtabletsin0.5%SDS);VIN:vinpocetine;
CA: citric acid.
promoting dissolving agent. It increased the dissolution of
VIN and subsequently prevented precipitation of VIN.
Figures 4 and 5 also showed that drug release of each
time point in 0.1N HCL media was higher than in 0.5%
SDS solution, especially after 8h. On the other hand, the
result showed that in 0.1N HCL media the cumulative drug
release percents of formulations whose ratios of VIN and
citric acid were higher than 1:1 had no diﬀerence and all
above90%after24h;however,in0.5%SDStheformulations
was 1:7/3. The results suggested that certain of H+ in release
media could penetrate through the semipenetrating mem-
brane which resulted in increasing the drug dissolubility.Advances in Pharmacological Sciences 5
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Figure 6: Release proﬁle of optimal osmotic pump tablets formu-
lation in diﬀe r e n tr e l e a s em e d i a :w a t e r ,0 . 1NH C L ,0 . 5 %S D S ,P B S
pH 6.8, 0.5% SDS PBS (pH 6.8).
Thereof, only the VIN of core tablet should meet certain
dissolubility,coulddiﬀerentmediabeappliedtotestdiﬀerent
formulations.
Table 2 showed that cumulative release of coating tablets
in 0.5% SDS were higher than core tablets in water, which
suggested that certain amount of drug could be pumped
from the drug release pore by the osmotic pressure power.
The results reproved the mechanism of osmotic pump tablet.
In the following, we selected diﬀerent release media-
water, 0.1N HCL, 0.5% SDS solution, 0.5% SDS PBS (pH
6.8), and PBS (pH 6.8) to test the release proﬁle. The release
proﬁles (Figure 6) in-water, 0.1N HCL, 0.5% SDS solution,
0.5% SDS PBS (pH 6.8) had no diﬀerences; but in PBS (pH
6.8) was slower, especially cumulative release decreasing after
8h which suggested the VIN-H+ had changed into free base
in pH 6.8 condition. So, it could be deduced that the citric
acid in formulation had a little eﬀect on the structure and
properties of VIN and absorption in the intestine.
In order to validate thoroughly whether the structure
of VIN changed, release solution after 24h of formulation
a n dd e - a c e t y l - V I Nh a db e e nd e t e c t e db yH P L C( F i g u r e s7(a)
and 7(b)). It was found that the chromatograph peak of de-
acetyl-VIN did not appear in the release solution of formu-
lation after 24h, which indicated that the citric acid had
no eﬀect on the structure of VIN. It was suggested that the
citric acid could have had a relation with changing the drug
microenvironment pH to increase the drug dissolubility and
release percent, which was diﬀerent from the viewpoint [10].
The optimal VIN EOPT was found to be able to deliver
VIN at a rate of approximately zero order up to 12h
in water, cumulative release at 12h is above 80%. From
the drug release mechanism of the EOPT, the application
of EOPT designed in the current study was dependent
on the drug solubility with increasing the organic acid.
In conclusion, VIN EOPT designed in the present study
was a good controlled delivery system for water-insoluble
base type drugs. During the developing VIN elementary
Table 4: The pharmacokinetic parameters (vinpocetine) in dogs
after oral administration of 15mg vinpocetine osmotic pump
controlled release tablets and immediate release-tablets (average ±
SD, n = 6).
Parameters Immediate release
tablets
Osmotic pump
controlled release
tablets
Tmax (h) 1.54 ± 0.64 4.83 ± 2.32∗
Cmax (ng/mL) 10.21 ± 1.55 3.62 ± 1.34∗
AUC (ng/mL·min) 34.80 ± 22.52 40.87 ± 17.75∗∗
T1/2 (h) 3.98 ± 1.06 3.77 ± 1.02∗∗
MRT (h) 13.76 ± 1.5 26.27 ± 2.1∗
Ke (h−1) 0.0756 ± 0.0164 0.0798 ± 0.0159∗∗
∗P<. 05, compared to the immediate release tablets (t-test)
∗∗P>. 05, compared to the immediate release tablets (t-test).
Table 5: The pharmacokinetic parameters (vinpocetine metabolite
apovincaminic acid) in dogs after oral administration of 15mg
vinpocetineosmoticpumpcontrolledreleasetabletsandimmediate
release-tablets (average ± SD, n = 6).
Parameters Immediate release
tablets
Osmotic pump
controlled release
tablets
Tmax (h) 1.67 ± 0.31 4.83 ± 1.02∗
Cmax (ng/mL) 149.28 ± 31.22 52.01 ± 22.39∗
AUC (ng/mL·min) 453.20 ± 57.55 377.19 ± 39.89∗∗
T1/2 (h) 4.63 ± 0.64 4.17 ± 0.22∗∗
MRT (h) 6.8 ± 0.86 17.29 ± 1.02∗
Ke (h−1) 0.0851 ± 0.0493 0.1067 ± 0.0981∗∗
∗P<. 05, compared to the immediate release tablets (t-test)
∗∗P>. 05, compared to the immediate release tablets (t-test).
osmotic pump tablet, it is found that H+ in release media
could be penetrating through the semipermeable membrane
and could be inﬂuencing the pH-dependent insoluble drug
release. In the following, in vivo evaluation was investigated.
3.2. Pharmacokinetic Studies. The pharmacokinetics of VIN
and its main metabolite, apovincaminic acid (AVA), were
studied in dogs. The mean dose-normalized plasma VIN
and apovincaminic acid (AVA) concentration-versus-time
proﬁles following administration of the EOP formulations
in beagle dogs are shown in (Figures 8 and 9). The pharma-
cokinetic parameters for VIN and apovincaminic acid (AVA)
are summarized in Tables 4 and 5.
The pharmacokinetic parameters of osmotic pump
tablets and immediate release tablets for VIN and its main
metabolite, apovincaminic acid (AVA), were Tmax (1.54 ±
0.64h) and (4.83 ± 2.32h), (1.67 ± 0.31h) and (4.83 ±
1.02h), Cmax (10.21 ± 1.55ng/mL) and (3.62 ± 1.34ng/mL),
and (149.28 ± 31.22ng/mL) and (377.19 ± 39.89ng/mL);
the relative bioavailability of the controlled release tablets
was 117.44%, 83.23%. Data in Figures 8 and 9 show similar
data published about VIN using orally administered [11]C -
labelled VIN and positron emission tomography in humans.
Guly´ as et al. [15] reported the Tmax of immediate release6 Advances in Pharmacological Sciences
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Figure 7: Chromatograph of de-acetyl-vinpocetine (a) and vinpocetine (b).
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Figure 8: The mean vinpocetine plasma concentration-time curves
of vinpocetine osmotic pump controlled-release tablets and imme-
diate release tablets after oral administration in dogs (n = 6).
tablets is about 2h in humans by the above method which
could be only in the initial distribution phase following oral
administration due to the fact that the half-life of [11]C -
labelled (20min).
Ac l e a rd i ﬀerence between the pharmacokinetic patterns
of VIN immediate release and VIN elementary osmotic
pump formulations was revealed. The area under the plasma
concentration-time curve after oral administration of ele-
mentary osmotic pump formulations was equivalent to VIN
immediate release formulation. Furthermore, signiﬁcant
diﬀerences (P<. 05, t-test) found for mean residence time,
Tmax and Cmax (Tables 4 and 5), corroborated prolonged
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Figure 9: The mean vinpocetine metabolite apovincaminic acid
(AVA) plasma concentration-time curves of vinpocetine osmotic
pump controlled-release tablets and immediate release tablets after
oral administration in dogs (n = 6, VIN: Vinpocetine).
releaseofVINfromelementaryosmoticpumpformulations.
These results suggest that the VIN (water-insoluble base type
drug) osmotic pump controlled release tablets with citric
acid have marked controlled release characters and the VIN
osmotic pump controlled release tablets and the normal
tablets were bioequivalent.
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